The aim of this project, which was commissioned by NICE through the NIHR HTA Programme as part of the NICE’s Fast Track Appraisal process, was to review the evidence for the clinical and cost-effectiveness of Aflibercept for treatment of myopic choroidal neovascularisation (mCNV). The clinical evidence submitted by the company (Bayer Pharma AG) responsible for manufacturing Aflibercept (Eylea) consisted of one RCT assessing Aflibercept versus sham-controlled injections. The Aberdeen HTA Group acted as the Evidence Review Group (ERG) for the project and provided an independent critique of the clinical and cost-effectiveness evidence submitted by the company.
After taking into consideration the company submission and the findings of the ERG’s critique, NICE released a technology appraisal guidance (TA486, November 2017). Aflibercept is currently recommended by NICE, within its marketing authorisation, as an option for treating visual impairment because of myopic choroidal neovascularisation in adults, only if the company provides Aflibercept in line with the commercial access agreement with NHS England. If patients and their clinicians consider both Aflibercept and ranibizumab to be suitable treatments, the least costly should be used, taking into account anticipated administration costs, dosage and price per dose.
Miriam Brazzelli; firstname.lastname@example.org
Brazzelli, M, Cummins, E, Fielding, S, Cruickshank, M, Fraser, C, Azuara-Blanco, A. Aflibercept for treating myopic choroidal neovascularisation. Fast track appraisal: cost comparison case. Evidence Review Group Report in support of NICE Fast Track Appraisal Programme. London: National Institute for Health and Care Excellence; 2017. URL: https://www.nice.org.uk/guidance/ta486/documents/committee-papers